Overview

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

Status:
Terminated
Trial end date:
2020-08-19
Target enrollment:
Participant gender:
Summary
This study is to evaluate the combination of an investigational drug X-82 with everolimus in the treatment of pancreatic neuroendocrine tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
Tyrogenex
Treatments:
Everolimus
Sirolimus